Ze Cong

621 total citations
44 papers, 455 citations indexed

About

Ze Cong is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Ze Cong has authored 44 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 18 papers in Public Health, Environmental and Occupational Health and 14 papers in Genetics. Recurrent topics in Ze Cong's work include Acute Lymphoblastic Leukemia research (17 papers), Hemoglobinopathies and Related Disorders (10 papers) and Iron Metabolism and Disorders (9 papers). Ze Cong is often cited by papers focused on Acute Lymphoblastic Leukemia research (17 papers), Hemoglobinopathies and Related Disorders (10 papers) and Iron Metabolism and Disorders (9 papers). Ze Cong collaborates with scholars based in United States, United Kingdom and Australia. Ze Cong's co-authors include Xue Song, Kathleen Wilson, Shravanthi R. Gandra, Ruben G.W. Quek, Robert Fowler, Karen Chung, Katherine Cappell, Thomas E. Delea, Janet Franklin and May Hagiwara and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Health Affairs.

In The Last Decade

Ze Cong

42 papers receiving 447 citations

Peers

Ze Cong
C.A. Uyl-de Groot Netherlands
Anna Moseley United States
Andrew Hantel United States
Moshe H. Erder United States
Binay Kumar Shah United States
Rejiv Rajendranath India
AH Partridge United States
S J Lee United States
Jane Jijun Liu United States
Karen Phekoo United Kingdom
C.A. Uyl-de Groot Netherlands
Ze Cong
Citations per year, relative to Ze Cong Ze Cong (= 1×) peers C.A. Uyl-de Groot

Countries citing papers authored by Ze Cong

Since Specialization
Citations

This map shows the geographic impact of Ze Cong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ze Cong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ze Cong more than expected).

Fields of papers citing papers by Ze Cong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ze Cong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ze Cong. The network helps show where Ze Cong may publish in the future.

Co-authorship network of co-authors of Ze Cong

This figure shows the co-authorship network connecting the top 25 collaborators of Ze Cong. A scholar is included among the top collaborators of Ze Cong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ze Cong. Ze Cong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cong, Ze, et al.. (2024). Perceptions of multi-cancer early detection (MCED) screening tests among underrepresented populations.. Journal of Clinical Oncology. 42(16_suppl). e22546–e22546. 1 indexed citations
2.
Ershler, William B., Laura M. De Castro, Zahra Pakbaz, et al.. (2023). Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease. Current Therapeutic Research. 98. 100696–100696. 4 indexed citations
3.
Cong, Ze, et al.. (2023). Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis. Journal of Managed Care & Specialty Pharmacy. 29(6). 659–670. 5 indexed citations
4.
Gidman, Wendy, Lirong Zhang, Jan McKendrick, et al.. (2019). Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study. Advances in Therapy. 36(11). 3017–3029. 5 indexed citations
5.
Bassan, Renato, Dieter Hoelzer, Xavier Thomas, et al.. (2019). Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study. Advances in Therapy. 36(4). 870–879. 4 indexed citations
6.
7.
Song, Jinlin, Qiufei Ma, Wei Gao, et al.. (2019). Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. Advances in Therapy. 36(4). 950–961. 20 indexed citations
8.
Pigneux, Arnaud, Pau Montesinos, Ze Cong, et al.. (2018). Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. BMC Cancer. 18(1). 1100–1100. 11 indexed citations
9.
Zhang, Xinke, et al.. (2018). Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States. Clinical Therapeutics. 40(10). 1711–1719.e1. 4 indexed citations
10.
Topp, Max S., Paul Cannell, Hervé Dombret, et al.. (2018). Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 131(26). 2906–2914. 36 indexed citations
11.
12.
13.
Song, Xue, et al.. (2017). Economic Burden of Veno-Occlusive Disease (VOD) in Patients with Acute Lymphoblastic Leukemia (ALL) in the US. Blood. 130. 5611–5611. 1 indexed citations
14.
15.
Song, Xue, Ze Cong, & Kathleen Wilson. (2015). Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Current Medical Research and Opinion. 32(1). 95–103. 67 indexed citations
16.
Song, Xue, Ruben G.W. Quek, Shravanthi R. Gandra, et al.. (2015). Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures. BMC Health Services Research. 15(1). 245–245. 63 indexed citations
17.
Hagiwara, May, Thomas E. Delea, Ze Cong, & Karen Chung. (2013). Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Supportive Care in Cancer. 22(1). 103–113. 20 indexed citations
18.
Breda, Arletta van, et al.. (2013). Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology Practices. Clinical Drug Investigation. 33(5). 383–389. 1 indexed citations
19.
Stopeck, Alison, Michael Rader, David Henry, et al.. (2012). Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics. 15(4). 712–723. 48 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C.A. Uyl-de Groot Breakdown of academic impact, for papers by Anna Moseley Breakdown of academic impact, for papers by Andrew Hantel Breakdown of academic impact, for papers by Moshe H. Erder Breakdown of academic impact, for papers by Binay Kumar Shah Breakdown of academic impact, for papers by Rejiv Rajendranath Breakdown of academic impact, for papers by AH Partridge Breakdown of academic impact, for papers by S J Lee Breakdown of academic impact, for papers by Jane Jijun Liu Breakdown of academic impact, for papers by Karen Phekoo
Rankless by CCL
2026